Get the Stockscreener App
16.51
5.97%
0.93
After Hours:
16.50
-0.01
-0.06%
Novocure Ltd stock is traded at $16.51, with a volume of 872.12K.
It is up +5.97% in the last 24 hours and down -14.59% over the past month.
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
See More
Previous Close:
$15.58
Open:
$16
24h Volume:
872.12K
Relative Volume:
1.05
Market Cap:
$1.79B
Revenue:
$577.74M
Net Income/Loss:
$-149.78M
P/E Ratio:
-11.79
EPS:
-1.4
Net Cash Flow:
$-78.21M
1W Performance:
+0.30%
1M Performance:
-14.59%
6M Performance:
+2.23%
1Y Performance:
+39.56%
1-Day Range:
$16.00
$16.60
1-Week Range:
$15.25
$16.60
52-Week Range:
$11.70
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Name
Novocure Ltd
Sector
Industry
Phone
44 (0)15 3475 6700
Address
NO. 4 THE FORUM, ST. HELIER
Compare NVCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
16.51 | 1.79B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-28-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-08-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-04-23 | Initiated | SVB Securities | Outperform |
| Jul-31-23 | Upgrade | Evercore ISI | Underperform → In-line |
| Jun-07-23 | Upgrade | Wedbush | Underperform → Neutral |
| May-16-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-05-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-29-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-24-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-05-22 | Downgrade | Evercore ISI | In-line → Underperform |
| May-16-22 | Initiated | H.C. Wainwright | Buy |
| Feb-08-22 | Initiated | Loop Capital | Buy |
| Feb-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| Jan-03-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Jul-01-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-14-21 | Downgrade | Wedbush | Neutral → Underperform |
| Jan-25-21 | Reiterated | Piper Sandler | Overweight |
| Sep-23-20 | Initiated | Northland Capital | Outperform |
| Sep-18-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-17-20 | Downgrade | Truist | Buy → Hold |
| Jun-01-20 | Resumed | Oppenheimer | Perform |
| May-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Mar-05-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-19 | Upgrade | SunTrust | Hold → Buy |
| Jul-26-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-19 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Nov-02-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-16-18 | Initiated | Evercore ISI | Outperform |
| Apr-18-18 | Reiterated | Mizuho | Buy |
| Feb-23-18 | Reiterated | Mizuho | Buy |
| May-24-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jul-29-16 | Reiterated | Wedbush | Outperform |
| Jan-19-16 | Initiated | Barclays | Underweight |
| Dec-02-15 | Initiated | Deutsche Bank | Hold |
View All
Novocure Ltd Stock (NVCR) Latest News
Novocure sees 6% spike from EU nod for electric lung cancer therapy gadget - Mugglehead Magazine
Novocure (NVCR) Gains CE Mark for Optune Lua in Lung Cancer Treatment | NVCR Stock News - GuruFocus
Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer | NVCR Stock News - GuruFocus
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer - Yahoo Finance
LPL Financial LLC Acquires Shares of 27,861 NovoCure Limited (NASDAQ:NVCR) - Defense World
Wedbush Issues Pessimistic Forecast for NovoCure Earnings - Defense World
NovoCure (NASDAQ:NVCR) vs. Sonoma Pharmaceuticals (NASDAQ:SNOA) Financial Review - Defense World
NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Why NovoCure Stock Was Withering on Wednesday - MSN
NovoCure (NASDAQ:NVCR) Upgraded to “Hold” at StockNews.com - Defense World
Why NovoCure (NVCR) Stock Fell Today - GuruFocus
Novocure price target lowered to $27 from $29 at Wedbush - TipRanks
Wedbush Adjusts Price Target for Novocure (NVCR) Ahead of Earnings Report | NVCR Stock News - GuruFocus
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
JPMorgan Chase & Co. Has Lowered Expectations for NovoCure (NASDAQ:NVCR) Stock Price - Defense World
11,672 Shares in NovoCure Limited (NASDAQ:NVCR) Bought by Raymond James Financial Inc. - Defense World
NovoCure Escapes Investor Suit Over Cancer Therapy Trial Data - Bloomberg Law News
NovoCure (NASDAQ:NVCR) Lowered to Sell Rating by StockNews.com - Defense World
NovoCure (NASDAQ:NVCR investor three-year losses grow to 80% as the stock sheds US$133m this past week - simplywall.st
Thrivent Financial for Lutherans Reduces Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
Corebridge Financial Inc. Has $1.58 Million Holdings in NovoCure Limited (NASDAQ:NVCR) - Defense World
Novocure to Report First Quarter 2025 Financial Results - Yahoo Finance
Emerald Advisers LLC Takes Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Proficio Capital Partners LLC Acquires Shares of 30,158 NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
NovoCure Beats Investor Lawsuit Over Cancer Trial Data Results - Bloomberg Law News
Charles Schwab Investment Management Inc. Has $24.92 Million Stake in NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure Beats Investor Suit Over Cancer Therapy Trial Data (1) - Bloomberg Law News
NovoCure (NASDAQ:NVCR) Rating Increased to Hold at StockNews.com - Defense World
Bank of New York Mellon Corp Increases Stock Holdings in NovoCure Limited (NASDAQ:NVCR) - Defense World
An Analysis of NovoCure Ltd (NVCR)’s Potential Price Growth - Knox Daily
Novocure at Leerink’s Global Healthcare Conference: Expanding TTFields By Investing.com - Investing.com India
Novocure at Leerink’s Global Healthcare Conference: Expanding TTFields - Investing.com
Principal Financial Group Inc. Invests $272,000 in NovoCure Limited (NASDAQ:NVCR) - Defense World
Novocure Ltd. to Host Earnings Call - ACCESS Newswire
Truist Financial Corp Invests $340,000 in NovoCure Limited (NASDAQ:NVCR) - Defense World
Don't Ignore The Insider Selling In NovoCure - Simply Wall St
Novocure’s EVP sells shares worth $46,841 By Investing.com - Investing.com Australia
Insider Sell Alert: Frank Leonard Sells 15,036 Shares of NovoCure Ltd (NVCR) - GuruFocus.com
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why - MSN
Novocure’s chief innovation officer sells shares worth $5,071 - Investing.com India
Novocure’s EVP sells shares worth $46,841 - Investing.com India
Novocure CEO Ashley Cordova sells shares valued at $38,055 By Investing.com - Investing.com South Africa
Novocure CEO Ashley Cordova sells shares valued at $38,055 - Investing.com
Novocure COO sells shares worth $4,634 By Investing.com - Investing.com Australia
Novocure COO sells shares worth $4,634 - Investing.com
Novocure’s COO Paravasthu Mukund sells shares worth $39,687 By Investing.com - Investing.com Australia
Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference - Yahoo Finance
NovoCure (NASDAQ:NVCR) Lowered to “Sell” Rating by StockNews.com - Defense World
NovoCure Executives Cash In: Major Stock Sales Unveiled! - TipRanks
Insider Sell: Uri Weinberg Sells Shares of NovoCure Ltd (NVCR) - GuruFocus.com
Novocure Ltd Stock (NVCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):